http://publicationslist.org/data/j.moro/atom.xml Jose Morohttp://publicationslist.org/j.moro$basepathfavicon.icoRecent additions to Jose Moro's PublicationsList.org pagehttp://publicationslist.org/publications.png2007-10-01T07:23:44Z http://publicationslist.org/j.moro/refid16 2007-10-01T07:18:23Z

Dyslipidemia is a common problem among heart transplant (HT) recipients; it is a frequent risk factor in these patients that is exacerbated by immunosuppressive drugs. Statins are effective drugs to treat dyslipidemia in HT recipients, but control is suboptimal in some patients. Ezetimibe acts through inhibition of the enterohepatic recirculation, a mechanism different from but complementary to st...<br/><br/>J Moro, L Almenar, L Martínez-Dolz, M Izquierdo, J Agüero, I Sánchez-Lazaro, V Ortiz, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2389-2392<br/>

http://publicationslist.org/j.moro/refid17 2007-10-01T07:18:23Z

INTRODUCTION: Smoking is an important risk factor in any population group. According to previous studies, having been a smoker before heart transplantation (HT) confers a greater likelihood of developing any type of tumor or other complication after HT. Our objective was to determine the impact of having been a smoker before HT on survival, respiratory complications during the postoperative period...<br/><br/>I J Sánchez-Lázaro, L Almenar, L Martínez-Dolz, J Moro, V Ortiz-Martínez, M T Izquierdo, O Cano, J Agüero, F Buendía, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2377-2378<br/>

http://publicationslist.org/j.moro/refid2 2007-07-07T08:16:37Z

INTRODUCTION AND OBJECTIVES: Sleep apnea-hypopnea syndrome (SAHS) is a prevalent condition that has well-known cardiovascular repercussions. However, few published echocardiographic studies have investigated the abnormalities present at SAHS diagnosis or their relationship with syndrome severity. Our objective was to evaluate myocardial structural, functional and performance parameters in these pa...<br/><br/>José A Moro, Luis Almenar, Estrella Fernández-Fabrellas, Silvia Ponce, Rafael Blanquer, Antonio Salvador (2007) <i>Rev Esp Cardiol</i> <i></i> <i></i> 60: 6 589-596<br/>

http://publicationslist.org/j.moro/refid26 2007-10-01T07:19:20Z

BACKGROUND: Renal function deterioration is one of the main problems facing heart transplant recipients. The mammalian target of rapamycin (mTOR) inhibitors, in combination with or replacing calcineurin inhibitors, may help preserve renal function. The aim of this study was to evaluate the progression of renal function after switching the immunosuppressive regimen. PATIENTS AND METHODS: We studied...<br/><br/>J Moro, L Almenar, L Martínez-Dolz, J Agüero, J Rueda, M A Arnau, M Izquierdo, O Cano, I Sánchez-Lázaro, A Salvador (2007) <i>Transplant Proc</i> 39: 7 2135-2137<br/>

http://publicationslist.org/j.moro/refid3 2007-07-07T08:16:37Z

María T Izquierdo, Luis Almenar, Luis Martínez-Dolz, José A Moro (2007) <i>Rev Esp Cardiol</i> <i></i> <i></i> 60: 1 85-86<br/>

http://publicationslist.org/j.moro/refid1 2007-07-07T08:16:37Z

Research into hormone secretion by the heart and the release of such hormones in detectable amounts in response to given clinical conditions has provided new perspectives full of hopes but also uncertainties. These hormones, called natriuretic peptides, have diuretic, natriuretic and vasodilating properties. In heart failure, a relationship between ventricular dysfunction and the levels of these p...<br/><br/>Luis Almenar, Luis Martínez-Dolz, Jose Moro (2007) <i>Curr Opin Mol Ther</i> <i></i> <i></i> 9: 3 282-290<br/>

http://publicationslist.org/j.moro/refid18 2007-10-01T07:18:23Z

INTRODUCTION: Many studies have shown a detrimental effect of female donor gender on heart transplantation (HT) outcome. OBJECTIVE: We retrospectively evaluated our experience in HT to determine the effect of donor gender on early survival. MATERIALS AND METHODS: We divided the sample of 464 primary HT from November 1997 to September 2006 into 4 groups: G1, female donor to a male recipient; G2, ma...<br/><br/>M T Izquierdo, L Almenar, L Martínez-Dolz, J Moro, J Agüero, I Sánchez-Lázaro, O Cano, V Ortiz, R Sánchez, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2375-2376<br/>

http://publicationslist.org/j.moro/refid15 2007-08-09T11:32:09Z

José A Moro, Luis Almenar, Pilar Morales, Ana Osa (2007) <i>Med Clin (Barc)</i> 129: 7 <br/>

http://publicationslist.org/j.moro/refid25 2007-10-01T07:18:23Z

INTRODUCTION: The present study evaluated the clinical and hemodynamic situation of patients with advanced heart failure considered for heart transplantation (HT) to examine the possible impact of prior cardiac disease. METHODS: We analyzed the pretransplant clinical, echocardiographic, and hemodynamic parameters of 422 consecutive HT patients. Pediatric and heart plus lung transplants were exclud...<br/><br/>V Ortiz, L Martínez-Dolz, E Sánchez-Lacuesta, L Almenar, F Ten, L Andrés, J Moro, M T Izquierdo, J Agüero, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2341-2343<br/>

http://publicationslist.org/j.moro/refid19 2007-10-01T07:18:23Z

INTRODUCTION: Preoperative pulmonary hypertension is an adverse prognostic factor for early morbidity-mortality after heart transplantation (HT). The persistence of hypertension is likewise associated with a poorer patient prognosis. The present study investigated the evolution of right cardiac pressures in the first year after HT with respect to the background cardiac disease. METHODS: This study...<br/><br/>V Ortiz, L Martínez-Dolz, F Ten, L Almenar, E Sánchez-Lacuesta, J Moro, I Sánchez-Lázaro, R Sánchez-Soriano, O Cano, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2368-2371<br/>

http://publicationslist.org/j.moro/refid23 2007-10-01T07:18:23Z

OBJECTIVE: The objective of this study was to describe the clinical course of patients with chronic hepatitis C virus (HCV) infection undergoing heart transplantation (HT). MATERIALS AND METHODS: Among 499 patients transplanted in our hospital between January 1989 and September 2006, 11 subjects (2.2%) had chronic HCV infection. We analyzed liver function laboratory parameters pretransplantation a...<br/><br/>O Cano, L Almenar, L Martínez-Dolz, J Moro, M T Izquierdo, J Agüero, R Sánchez, V Ortiz, I Sánchez, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2353-2354<br/>

http://publicationslist.org/j.moro/refid24 2007-10-01T07:18:23Z

OBJECTIVE: The objective of this study was to compare baseline characteristics and long-term survival among patients undergoing heart transplantation (HT) according to the 3 main types of prior heart disease: ischemic, idiopathic dilated cardiomyopathy (IDC), and valvular. MATERIALS AND METHODS: Four hundred twenty-three HTs performed between 1989 and 2005 were included. We excluded pediatric tran...<br/><br/>J Agüero, L Almenar, L Martínez-Dolz, J Moro, M T Izquierdo, O Cano, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2350-2352<br/>

http://publicationslist.org/j.moro/refid22 2007-10-01T07:18:23Z

The number of congenital heart disease (CHD) patients transplanted to date is small. The results are comparable to those undergoing heart transplantation (HT) for other etiologies. However, advances in pediatric surgery over recent years (eg, the Fontan procedure) has increased the demand for HT by a growing number of children who reach adulthood and who also have a different profile. We analyzed ...<br/><br/>M T Izquierdo, L Almenar, L Martínez-Dolz, J Moro, J Agüero, I Sanchez-Lázaro, O Cano, V Ortiz, R Sánchez, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2357-2359<br/>

http://publicationslist.org/j.moro/refid21 2007-10-01T07:18:23Z

The 2006 International Society for Heart and Lung Transplantation registry reported that there were differences in mortality after heart-lung transplantation (HLT) depending on the etiology for transplantation. Our objective was to conduct an analysis on mortality after HLT at our center. MATERIALS AND METHODS: From January 1991 to December 2006, 25 HLT were performed on patients with the followin...<br/><br/>M T Izquierdo, L Almenar, P Morales, A Sole, R Vicente, L Martínez-Dolz, J Moro, J Agüero, I Sánchez-Lázaro, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2360-2361<br/>

http://publicationslist.org/j.moro/refid20 2007-10-01T07:18:23Z

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are relatively new drugs in the field of cardiac transplantation (HT), hence the need for further study of their secondary effects. We described the nature and incidence of secondary effects of these drugs in a group of HT recipients. PATIENTS AND METHODS: We studied 23 HT recipients aged 52 +/- 9 years (Male: 91%, body mass index: 27 +/-...<br/><br/>J Moro, L Almenar, L Martínez-Dolz, M Izquierdo, J Rueda, M A Arnau, J Agüero, I Sánchez-Lázaro, V Ortiz, A Salvador (2007) <i>Transplant Proc</i> <i></i> <i></i> 39: 7 2365-2367<br/>

http://publicationslist.org/j.moro/refid6 2007-07-07T08:16:37Z

INTRODUCTION: Graft vessel disease (GVD) is one of the main long-term complications in heart transplant (HT) patients. At present, the diagnosis of this complication requires invasive procedures. Multislice CT is an emerging technique that allows visualization of the coronary anatomy, including the vascular lumen and wall thickness. Our objective was to establish the value of 16-detector multislic...<br/><br/>J Moro, L Almenar, B Igual, L Martínez-Dolz, E Sánchez, J Martín, L Andrés, O Cano, C Chamorro, I Sánchez, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2563-2565<br/>

http://publicationslist.org/j.moro/refid5 2007-07-07T08:16:37Z

BACKGROUND: Cardiac allograft vasculopathy (CAV) is the leading cause of heart transplant failure after the first year. The etiological factors involved are currently a controversial matter. Intravascular ultrasound (IVUS) is considered the diagnostic procedure of choice. We assessed the relationship of cardiovascular risk factors with CAV. MATERIALS: We analyzed prospectively 22 patients. We cond...<br/><br/>C I Chamorro, L Almenar, L Martínez-Dolz, E Sánchez-Lacuesta, J Martín-Pastor, F Ten-Morro, R M Sánchez-Soriano, J Agüero, V Ortiz, J A Moro, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2572-2574<br/>

http://publicationslist.org/j.moro/refid4 2007-07-07T08:16:37Z

INTRODUCTION AND OBJECTIVES. At present, there is some controversy about the impact of diabetes mellitus on heart transplant patients. The effect of the disease on mortality and on other complications, such as infection or rejection, is unclear. The objective of this study was to investigate these factors in our heart transplant patients. METHODS. We studied 365 consecutive patients who underwent ...<br/><br/>José A Moro, Luis Martínez-Dolz, Luis Almenar, Luis Martínez-Ortiz, Carlos Chamorro, Carlos García, Miguel A Arnau, Joaquín Rueda, Esther Zorio, Antonio Salvador (2006) <i>Rev Esp Cardiol</i> <i></i> <i></i> 59: 10 1033-1037<br/>

http://publicationslist.org/j.moro/refid7 2007-07-07T08:16:37Z

OBJECTIVE: To evaluate the frequency of infection according to the immunosuppressive regimens used in our center. MATERIALS AND METHODS: From 259 consecutive heart transplants we excluded pediatric cases, retransplants, combined transplants (lung and kidney) and immunosuppressive regimens with fewer than 10 cases. The six groups analyzed were: (1) OKT3 (7 days) + cyclosporine (CsA) + mycophenolate...<br/><br/>J Agüero, L Almenar, L Martinez-Dolz, C Chamorro, J Moro, E Zorio, M A Arnau, J Rueda, M Izquierdo, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2558-2559<br/>

http://publicationslist.org/j.moro/refid11 2007-07-07T08:19:24Z

The use of amiodarone before transplantation has been linked to an increased number of complications, acute graft failures, and early mortality after a heart graft. We undertook a retrospective, descriptive, case-controlled study involving early mortality and acute graft failure. The 396 consecutive patients included 25 subjects who had been prescribed amiodarone for at least 30 days before transp...<br/><br/>I J Sánchez-Lázaro, L Almenar, L Martinez-Dolz, C Chamorro, J Moro, J Agüero, J Rueda, E Zorio, M A Arnau, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2537-2538<br/>

http://publicationslist.org/j.moro/refid12 2007-07-07T08:19:24Z

José A Moro, Miguel A Arnau, Elena Sánchez, Luis Almenar (2006) <i>Rev Esp Cardiol</i> <i></i> <i></i> 59: 6 632-633<br/>

http://publicationslist.org/j.moro/refid10 2007-07-07T08:19:24Z

Since their introduction onto the market, interleukin-2 antagonists have been increasingly used by a growing number of transplant units. Their benefits versus OKT3 appear evident, although the optimal dose remains to be established. Our objective was to establish possible differences related to the use of two versus five doses of daclizumab. MATERIALS AND METHODS: This study evaluated 81 consecuti...<br/><br/>V Ortiz, L Almenar, L Martínez-Dolz, E Zorio, C Chamorro, J Moro, J Agüero, J Rueda, M A Arnau, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2541-2543<br/>

http://publicationslist.org/j.moro/refid9 2007-07-07T08:19:24Z

OBJECTIVE: To perform an analysis comparing long-term survival in heart transplant (HT) patients depending on the immunosuppressive regimen. MATERIALS AND METHODS: The study included 317 consecutive HT patients. We excluded pediatric cases, retransplants, combined transplants (lung and kidney), and immunosuppressive regimens with fewer than 10 cases. The six groups analyzed were: (1) OKT3 7 days +...<br/><br/>J Agüero, L Almenar, L Martínez-Dolz, C Chamorro, J Moro, J Rueda, M A Arnau, E Zorio, M Izquierdo, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2550-2552<br/>

http://publicationslist.org/j.moro/refid8 2007-07-07T08:16:37Z

Patients with a heart transplant (HT) may require changes in their immunosuppressive maintenance medication. The basic treatment regimen in our patients consisted of an anticalcineurin agent, an antimetabolite, and a steroid. OBJECTIVE: We undertook a descriptive study to quantify the incidence and causes of these changes and determine how they occur. MATERIALS AND METHODS: We included the 432 HT ...<br/><br/>I Sánchez-Lázaro, L Almenar, L Martínez-Dolz, C Chamorro, J Moro, J Agüero, J Rueda, E Zorio, M A Arnau, A Salvador (2006) <i>Transplant Proc</i> <i></i> <i></i> 38: 8 2553-2554<br/>

http://publicationslist.org/j.moro/refid14 2007-07-07T08:19:24Z

BACKGROUND AND AIMS: Immunosuppressive therapy has undergone great changes in recent years as a result of the introduction of new drugs, presumed a prior to be more effective and better tolerated. The greatest advance seems to have been the introduction of interleukin-2 (IL-2) receptor antagonists. The objective of this study was to determine whether the use of IL-2 receptor antagonists in inducti...<br/><br/>L Almenar, C García-Palomar, L Martínez-Dolz, C Chamorro, J Moro, E Zorio, M A Arnau, J Rueda, A Osa, M L Cardo (2005) <i>Transplant Proc</i> <i></i> <i></i> 37: 9 4024-4027<br/>

http://publicationslist.org/j.moro/refid13 2007-07-07T08:19:24Z

INTRODUCTION: It is known that there is a high incidence of diabetes mellitus (DM) among heart transplant (HT) patients, which may be up to 30% at 5 years. The presence of DM has been associated with increased morbidity (infections, renal dysfunction, or graft vascular disease), and its development has been related primarily to immunosuppressive therapy. The objective of this study was to determin...<br/><br/>L Martínez-Dolz, L Almenar, L Martínez-Ortiz, M A Arnau, C Chamorro, J Moro, A Osa, J Rueda, C García, M Palencia (2005) <i>Transplant Proc</i> <i></i> <i></i> 37: 9 4064-4066<br/>